MIT | Academy of Engineering

(An Autonomous Institute Affiliated to Savitribai Phule Pune University)

A Project Report on

Alzheimer Disease Detection using OASIS Datasets

Submitted by,

Afsana Ansari	**(Exam Seat No. B234012)**
Akash Bhise	**(Exam Seat No. B234060)**
Anikat Raju	**(Exam Seat No. B234075)**
Shivansh Sharma	**(Exam Seat No. B234136)**

Guided by,

Mrs. Madhavi Nimkar

A Report submitted to MIT Academy of Engineering, Alandi(D), Pune, An Autonomous Institute Affiliated to Savitribai Phule Pune University in partial fulfillment of the requirements of

BACHELOR OF TECHNOLOGY in

Computer Engg.

School of Computer Engineering

MIT Academy of Engineering

(An Autonomous Institute Affiliated to Savitribai Phule Pune University)

Alandi (D), Pune – 412105

(2023-2024)

MIT | Academy of Engineering

(An Autonomous Institute Affiliated to Savitribai Phule Pune University)

CERTIFICATE

It is hereby certified that the work which is being presented in the BTECH Project Report entitled **"Alzheimer Disease Detection using OASIS Datasets"**, in partial fulfillment of the requirements for the award of the Bachelor of Technology in Computer Engg.and submitted to the **School of Computer Engineering** of **MIT Academy of Engineering, Alandi(D), Pune, Affiliated to Savitribai Phule Pune University (SPPU), Pune**, is an authentic record of work carried out during Academic Year **2023-2024**, under the supervision of **Mrs. Madhavi Nimkar**, **School of Computer Engineering**

Afsana Ansari	**(Exam Seat No. B234012)**
Akash Bhise	**(Exam Seat No. B234060)**
Anikat Raju	**(Exam Seat No. B234075)**
Shivansh Sharma	**(Exam Seat No. B234136)**

Mrs. Madhavi Nimkar	**Mr. Pranav Shriram**	**Dr. Rajeshwari Goudar**
Project Advisor	**Project Coordinator**	**Dean SCE**

Director/Dy. Director(AR) **External Examiner**

DECLARATION

We the undersigned solemnly declare that the project report is based on our own work carried out during the course of our study under the supervision of **Mrs. Madhavi Nimkar**.

We assert the statements made and conclusions drawn are an outcome of our project work. We further certify that

1. The work contained in the report is original and has been done by us under the general supervision of our supervisor.
2. The work has not been submitted to any other Institution for any other degree/diploma/certificate in this Institute/University or any other Institute/University of India or abroad.
3. We have followed the guidelines provided by the Institute in writing the report.
4. Whenever we have used materials (data, theoretical analysis, and text) from other sources, we have given due credit to them in the text of the report and giving their details in the references.

Afsana Ansari	**(Exam Seat No. B234012)**
Akash Bhise	**(Exam Seat No. B234060)**
Anikat Raju	**(Exam Seat No. B234075)**
Shivansh Sharma	**(Exam Seat No. B234136)**

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a significant impact on cognitive functions. Early and accurate diagnosis plays a crucial role in facilitating timely interventions and treatments. This research presents a comprehensive analysis and application of machine learning and deep learning techniques for the diagnosis and classification of Alzheimer's disease using diverse datasets.

The study encompasses the utilization of the OASIS CSV dataset, magnetic resonance imaging (MRI) data, and 3D imaging datasets. A systematic approach is employed, involving data preprocessing, feature extraction, and the application of various machine learning models, including ensemble learning algorithms and convolutional neural networks (CNNs). The OASIS CSV dataset is processed through a tailored pipeline, while MRI data is analyzed using specialized CNN architectures. Additionally, a 3D ResNet-18 model is implemented for the processing of volumetric 3D datasets.

The results demonstrate the effectiveness of the proposed methodologies, with high accuracy and performance metrics achieved across different datasets. The ensemble learning models applied to the OASIS CSV dataset exhibit compelling classification results. The 3D ResNet-18 architecture proves effective in handling volumetric data, contributing to advanced AD detection methodologies. The findings underscore the significance of leveraging diverse datasets and tailored processing pipelines for comprehensive AD diagnosis. The proposed methodologies not only contribute to the understanding of AD progression but also provide a foundation for the development of automated and precise diagnostic tools.

Acknowledgment

We take this opportunity to express our deep appreciation and gratitude to everyone who helped us complete this project on early detection of Alzheimer's disease using medical imagery and Ensemble learning.

First of all, we would like to express our sincere thanks to our project supervisor Ms. Madhavi Nimkar, for their invaluable guidance, support and mentorship throughout the project. Their extensive knowledge and expertise in machine learning and medical imaging has been instrumental in shaping our research direction and methodologies. We would also like to express our heartfelt thanks to our colleagues and classmates who provided us with valuable feedback, suggestions and motivation during the project. Their constructive criticism and insights helped us refine our research and improve the quality of our findings.

Finally, we would like to express our deepest gratitude to our families and friends who have supported us along this journey. Their encouragement, understanding and unwavering belief in us was instrumental in keeping us motivated and focused during challenging times.

Finally, we would like to thank everyone who contributed to the successful completion of this project. Your support and guidance have been invaluable in helping us achieve our goals. Thank you all for your contributions and support.

Contents

List of Figures

List of Tables

Chapter 1

Introduction

1.1 Background

Alzheimer's disease (AD) is a progressive and irreversible neuro-degenerative disease that mainly affects the elderly population, causing cognitive decline and memory loss. It is estimated that millions of people worldwide suffer from AD, making it an important public health problem. Early detection and accurate diagnosis of AD is essential to initiate appropriate interventions, provide better care, and improve patient outcomes.

Traditionally, the diagnosis of AD is based on clinical evaluation, cognitive assessment, and neuro-psychological testing. However, this method often lacks accuracy and may not detect the disease in the early stages when interventions may be more effective. Consequently, there is increasing interest in using advanced machine-learning techniques and medical imaging data to develop automatic and objective approaches for AD detection.

In recent years, the availability of large-scale databases has empowered researchers to develop and assess machine-learning algorithms for Alzheimer's disease (AD) detection. The Oasis-1 longitudinal database, a significant resource, furnishes valuable information on individuals with and without dementia, enabling exploration of machine learning models to differentiate these groups and identify AD-associated features. Additionally, the use of magnetic resonance imaging (MRI) datasets offers detailed

visualization of brain structures, providing insights into structural changes linked to AD progression. Coupled with the Oasis-1 database, another crucial dataset involves 3D imaging data in the form of NIfTI files, containing volumetric information about brain structures. This comprehensive approach allows for a deeper understanding of the structural changes associated with AD progression.

1.2 Project Idea

This project aims to evaluate the performance of three distinct datasets - the Oasis-1 longitudinal database, MRI image dataset, and 3D imaging dataset - in the context of Alzheimer's Disease (AD) detection. Through the application of machine learning algorithms and medical imaging techniques, the primary objective is to enhance the accuracy and timeliness of AD diagnosis.

The Oasis-1 longitudinal database, a valuable resource detailing information about smoking and non-smoking individuals over time, will be explored using an ensemble learning approach. Various machine-learning models will be trained and evaluated to differentiate individuals with and without dementia, revealing patterns and characteristics associated with AD.

Simultaneously, a dataset of MRI images representing different stages of dementia severity will be leveraged. Utilizing a Convolutional Neural Network (CNN), the goal is to extract relevant features from MRI images and predict dementia severity, providing a quantitative measure of disease progression.

The project also incorporates 3D imaging data in NIfTI files, representing volumetric brain information. Employing ResNet3D, spatial alterations within the brain associated with AD progression will be examined to identify significant patterns.

The project aims to compare the effectiveness of three datasets and methodologies for Alzheimer's Disease (AD) detection, evaluating strengths, limitations, and potential clinical applicability. Emphasizing the development of diagnostic tools, it seeks to enhance understanding of AD's underlying mechanisms and identify bio-markers. The overarching goal is to enable early intervention, leading to improved patient

outcomes and targeted treatment strategies. In alignment with the growing interest in utilizing machine learning and medical imaging for AD diagnosis, the project leverages the Oasis-1 longitudinal database, MRI image database, and 3D imaging to contribute significantly to AD detection and patient care. This initiative represents a compelling opportunity to explore innovative approaches, aiming for early and accurate diagnosis to enhance patient management and treatment outcomes.

1.3 Motivation

1.3.1 Growing Global Burden of AD:

Alzheimer's Disease (AD) presents a formidable challenge globally, impacting millions and necessitating advanced diagnostic tools. The urgency arises from the progressive nature and widespread prevalence of AD, underlining the critical need for timely diagnosis, intervention, and effective treatment strategies.

1.3.2 Potential of Machine Learning and Imaging Technologies:

Advancements in machine learning and medical imaging technologies, including ensemble learning, CNNs, and specialized architectures like ResNet3D, offer promising avenues for comprehensive AD detection.

1.3.3 Significance of Diverse Datasets:

The integration of diverse datasets - Oasis-1 longitudinal database, MRI images, and 3D imaging datasets - provides a multidimensional understanding of AD pathology, enhancing diagnostic accuracy by capturing intricate patterns, structural changes, and biomarkers.

1.3.4 Advancing Early Intervention and Patient Outcomes:

Early AD detection not only facilitates timely interventions but also opens avenues for targeted treatment strategies, potentially transforming patient outcomes and improving their quality of life.

The project aims to significantly impact Alzheimer's Disease (AD) diagnosis by providing insights into superior methodologies. This knowledge could lead to the development of more accurate diagnostic tools, aiding timely and informed patient care decisions. Beyond immediate clinical applications, the outcomes may have broader implications for personalized medicine in neurodegenerative disorders. Through the use of reliable machine learning models and medical imaging data, the project seeks to enhance AD diagnosis accuracy, enabling early intervention and personalized treatment strategies. Driven by the urgent need to address AD diagnosis challenges, the project aspires to leverage advanced technologies and diverse datasets to create robust, early, and accurate diagnostic tools, ultimately aiming to improve patient outcomes and revolutionize AD management.

1.4 Project Challenges

Developing advanced methods for Alzheimer's Disease (AD) detection through machine learning and medical imaging presents several challenges that are essential to overcome for the effective advancement of the field. This exploration encompasses various facets of the project, addressing the hurdles faced:

1.4.1 Data Heterogeneity and Quality:

Managing diverse datasets like the Oasis-1 longitudinal database, MRI images, and 3D imaging introduces challenges in handling varying structures, formats, and quality levels. Ensuring data uniformity, addressing missing values, and managing data preprocessing complexities are critical tasks.

1.4.2 Feature Extraction and Selection:

Extracting meaningful features from different data modalities and identifying the most relevant ones for AD detection is challenging. The complexity of medical imaging data necessitates sophisticated feature selection methods to prevent information overload and overfitting.

1.4.3 Model Generalization and Performance:

Developing machine learning models that generalize well across datasets and accurately predict AD poses challenges related to overfitting, model bias, and capturing subtle patterns associated with AD progression without misclassification.

1.4.4 Interpretability of Model Outputs:

Ensuring the interpretability of complex models, especially in medical contexts, is crucial. Translating model predictions into clinically meaningful insights for healthcare practitioners faces challenges, particularly with the black-box nature of complex models like CNNs.

1.4.5 Integration of Multimodal Data:

Fusing information from diverse datasets while maintaining their individual strengths is challenging. Harmonizing different data representations and modalities to yield a comprehensive understanding of AD pathology adds complexity.

1.4.6 Limited Labeling and Ground Truths:

The limited availability of labeled data, especially in longitudinal datasets, could hinder model training. Obtaining accurate ground truths, particularly in medical imaging, poses challenges in acquiring annotated datasets for training robust models.

1.4.7 Ethical and Regulatory Considerations:

Ensuring compliance with ethical guidelines, patient privacy, and regulatory requirements concerning patient data, particularly sensitive medical information, adds layers of complexity to data acquisition and usage.

1.4.8 Clinical Translation and Validation:

Translating research findings into clinically applicable tools and validating methodologies in real-world clinical settings is challenging. Bridging the gap between research outcomes and practical clinical utility demands extensive validation and acceptance within the medical community.

In conclusion, collaborative efforts, interdisciplinary expertise, and innovative methodologies are essential to address these multifaceted challenges. Overcoming these hurdles is crucial for the successful development and deployment of accurate, reliable, and clinically relevant diagnostic tools for Alzheimer's Disease. If necessary, considerations related to data sharing agreements with the Oasis dataset have been adhered to.

1.5 Proposed Solution

In this project, we present a comprehensive solution using machine learning algorithms and medical imaging for enhanced Alzheimer's Disease (AD) detection and diagnosis. Our approach incorporates three databases: the Oasis-1 longitudinal database, the MRI image database, and 3D imaging. Employing ensemble learning models, Convolutional Neural Networks (CNNs), and ResNet3D, we aim for accurate and reliable AD detection.

For the Oasis-1 longitudinal dataset, we propose an ensemble learning approach that combines decision trees, random forests, and gradient boosting. This method leverages the strengths of multiple models to achieve greater accuracy in distinguishing between demented and non-demented individuals.

Utilizing MRI image data, we deploy a CNN model to extract meaningful features and patterns, predicting dementia severity. CNNs are well-suited for image analysis tasks, automatically learning hierarchical representations from the input data.

Additionally, 3D imaging data from NIfTI files is incorporated, providing volumetric information about brain structures. Employing the ResNet3D architecture tailored for three-dimensional data, we aim to extract spatial features related to AD progression, uncovering subtle structural alterations indicative of the disease.

Integration of ResNet3D with the Oasis-1 dataset and MRI images enhances our understanding of AD pathology, capturing intricate spatial variations within brain structures. The evaluation involves comparing ensemble learning, CNNs, and ResNet3D methodologies across metrics like accuracy, precision, recall, and ROC curves, as well as considering interpretability, computational complexities, and clinical relevance. This comprehensive assessment guides potential adoption in clinical practice, aiming to enhance AD diagnosis accuracy and patient care strategies.

In conclusion, our proposed solution combines diverse methodologies for AD detection, showcasing their unique strengths and contributions. The collective evaluation underscores the importance of integrating approaches for improved accuracy and comprehensive understanding of AD pathology, with potential implications for advancing healthcare practices and patient outcomes in neurodegenerative diseases.

1.6 Major Contribution

This project advances AD detection methodologies by integrating machine learning and medical imaging across diverse datasets. Through a comprehensive evaluation of ensemble learning, CNNs, and ResNet3D, the project showcases an interdisciplinary approach to address neurodegenerative disease challenges. By seamlessly bridging machine learning and medical imaging, it aims to develop accurate, early, and clinically applicable AD diagnostic tools. The evaluation on datasets like Oasis-1, MRI images, and 3D imaging provides insights into AD pathology, spatial variations, and biomarkers. This foundational work sets the stage for an integrated diagnostic frame-

work, influencing future research and contributing to AD detection advancements.

- **Methodological Advancement:** The project significantly advances AD detection methodologies by integrating machine learning and medical imaging techniques.
- **Comprehensive Evaluation:** Three distinct methodologies – ensemble learning, CNNs, and ResNet3D – are meticulously evaluated and compared for their effectiveness in deciphering AD pathology.
- **Interdisciplinary Approach:** The project represents a leap forward in amalgamating interdisciplinary techniques to address the challenges of neurodegenerative diseases.
- **Bridge Between Fields:** By bridging machine learning and medical imaging, the project aims to create more accurate, early, and clinically applicable diagnostic tools for AD.
- **Dataset Integration:** Thorough assessment and comparative analysis are conducted on datasets, including Oasis-1 longitudinal database, MRI images, and 3D imaging.
- **Insights into AD Progression:** Insights derived from analyses uncover patterns, spatial variations, and biomarkers associated with AD progression across different data modalities, facilitating early diagnosis and disease monitoring.
- **Integrated Diagnostic Framework:** The project lays the groundwork for an integrated diagnostic framework leveraging the strengths of ensemble learning, CNNs, and ResNet3D.
- **Clinical Implications:** Findings have profound implications for clinical practice, indicating potential applicability in aiding healthcare practitioners for early AD detection, patient stratification, and guiding targeted treatment strategies.
- **Pathway for Future Research:** The project contributes to a pathway for future research in advancing AD detection methodologies.

1.7 Project Report Organization (Chapter wise summary)

In the introductory chapter, the background, project idea, and motivations are outlined, emphasizing the urgency to address the global burden of AD. The subsequent chapter conducts a thorough literature review, exploring related work, the state of the art, and product surveys in AD detection. Limitations of current techniques are discussed, opening avenues for future research. Chapter three defines the problem statement, project goals, and objectives, along with outlining the scope and constraints. It further details the hardware and software requirements and expected outcomes. Chapter four delves into the system requirement specifications, including product perspectives, user characteristics, and project planning. The methodology chapter provides insights into the system architecture, mathematical modeling, and the overall approach undertaken. The practical implementation of the system, result analysis, and performance evaluation are presented in chapters six and seven, respectively. Finally, the report concludes with a summary of key findings and future research directions. Appendices include supplementary materials, certificates, and a reference section listing the sources used throughout the report.

Chapter 2

Literature Review

2.1 Related work And State of the Art (Latest work)

In recent times, there has been a lot of interest in the potential of utilising MRI and PET scan data to detect Alzheimer's disease as a means of accurately and early diagnosing the condition. Prior research has demonstrated that deep learning algorithms may use this imaging modality to precisely and highly specifically diagnose Alzheimer's disease. Additionally, a number of studies have discovered imaging biomarkers linked to Alzheimer's disease, including modifications to the brain's connections, structure, and metabolism. In specifically, convolutional neural networks, feature extraction and selection methods, and training are machine learning approaches that have been used in research to identify Alzheimer's disease. In this case, understanding the work in this area can provide insight into the state of the art and inform the development of new approaches for early and accurate diagnosis of Alzheimer's disease using MRI and PET scan data.

Below are the detailed work founded in the context of the problem statement.

One study suggests using brain PET scans to diagnose Alzheimer's disease using a deep learning-based method. The researchers employed deep learning algorithms to precisely diagnose Alzheimer's disease with high sensitivity and specificity using a dataset of PET scans from patients with the illness and healthy controls. According to the study, PET imaging may be a helpful method for accurately and early

Alzheimer's disease diagnosis. Franc, Yiming Ding, 1992)

The next study suggests using MRI data to accurately predict Alzheimer's disease using a deep learning-based method. A convolutional neural network (CNN) model that the scientists created was very successful at differentiating between Alzheimer's sufferers and healthy controls. According to the study, Alzheimer's illness may be accurately identified using deep learning models employing MRI data. (Orouskhani, Maysam, 2022).

A thorough analysis of the many deep learning algorithms and machine learning approaches employed in the neuroimaging-based Alzheimer's disease diagnosis is also given in one of the articles. The performance of several techniques, such as support vector machines, random forests, convolutional neural networks, and autoencoders, is compared and examined by the writers. They also discuss the challenges and limitations of these approaches and suggest potential future directions for research in this field. The review highlights the potential of machine learning and deep learning in accurately diagnosing Alzheimer's disease and improving patient outcomes. (Zhao Z, 2023)

The study on the combination of MRI and machine learning algorithms for enhanced Alzheimer's disease detection is presented in the following publication. The scientists employed a variety of machine learning techniques, such as Random Forest (RF) and Support Vector Machines (SVMs), to classify a dataset of MRI scans. They discovered that integrating different MRI scan modalities increased the classification algorithms' accuracy. According to the study, multimodal machine learning techniques may be helpful in the early diagnosis of Alzheimer's. (G. Battineni, 2021)

An alternative article suggests using deep learning to forecast Alzheimer's using MRI pictures of people who have moderate cognitive impairment. The suggested approach may prove to be a useful tool for early diagnosis, as the authors employed Convolutional Neural Networks (CNNs) for picture analysis and showed high accuracy in predicting Alzheimer's disease. The work emphasises the potential of MRI image analysis with deep learning as a non-invasive and successful method for Alzheimer's disease prediction. (W Lin, 2018a)

The study suggests a unique method for detecting Alzheimer's early on utilising magnetic resonance imaging (MRI) in conjunction with ensemble learning and convolutional neural networks (CNNs). The scientists employed CNNs to extract characteristics from an image dataset consisting of MRI scans from patients with Alzheimer's disease, moderate cognitive impairment, and healthy controls. The collected features were then combined using an ensemble learning technique to enhance the classification performance. The study achieved high accuracy in predicting Alzheimer's disease, suggesting that the proposed approach could be a promising tool for early detection of the disease. (Lin W, 2018b)

A deep learning-based method for the early identification of Alzheimer's disease using multimodal neuroimaging data is suggested in one of the study publications. The authors created a novel deep learning architecture that combines Long Short-Term Memory (LSTM) networks and Convolutional Neural Networks (CNNs) to analyse multiple neuroimaging modalities, including biomarkers for cerebrospinal fluid (CSF), fluorodeoxyglucose-positron emission tomography (FDG-PET), and magnetic resonance imaging (MRI). The proposed model achieved high accuracy in predicting the Alzheimer's disease stage, demonstrating the potential of deep learning and multimodal data analysis as a promising technique for early detection of Alzheimer's disease.(Venugopalan, Tong, Hassanzadeh, Wang, 2021)

In the study of S. Kim et al., a deep learning-based method for categorising amyloid PET positive using 2-[18F]FDG PET imaging is proposed for the Alzheimer's disease continuum. The scientists employed deep learning algorithms, such as convolutional neural networks (CNNs), for picture categorization using a sizable dataset of PET images from Alzheimer's patients and healthy controls. They predicted amyloid PET positive with a high degree of accuracy, indicating that this method may be helpful for Alzheimer's disease early diagnosis and disease progression tracking. The study highlights the potential of deep learning and multimodal imaging for improving the accuracy and efficiency of Alzheimer's disease diagnosis.(Kim S, 2021)

The onset of Alzheimer's disease was identified using MRI and PET 10 neuroimaging techniques, according to the longitudinal data analysis and machine learning study.

The research was approved for web publishing on March 3, 2023, and was carried out between August 2022 and January 2023. Iroshan Aberathne, Don Kulasiri, and Sandhya Samarasinghe are the research's authors.

A machine learning-based system for brain MRI analysis-based Alzheimer's disease identification is presented in the paper by Mustafa Kamal et al. The scientists created an evolutionary system to extract information from MRI scans and categorise them as Alzheimer's or non-Alzheimer's using image processing and machine learning approaches. The suggested framework showed promise as a non-invasive diagnostic tool by diagnosing Alzheimer's disease with high accuracy. The study highlights the usefulness of machine learning and MRI analysis for early detection and diagnosis of Alzheimer's disease. (Koundal, 2022)

The study by Narotam Singh et al. offers a thorough analysis of current research that has employed deep learning algorithms for automated MRI image-based Alzheimer's disease identification. The writers go over a number of deep learning methods, including autoencoders, recurrent neural networks, and convolutional neural networks (CNNs), and how these might be used to diagnose Alzheimer's disease. They also point out the drawbacks and restrictions of the approaches used now and make recommendations for future lines of inquiry. The review emphasizes the potential of deep learning in improving the accuracy and efficiency of Alzheimer's disease diagnosis. (Singh, D, Soni, Kapoor, 2022)

In their publication, K. Etminani et al. describe a deep learning model that uses 18F-FDG PET images to diagnose various forms of dementia. The scientists trained a 3D convolutional neural network to categorise a sizable dataset of PET images from individuals with moderate cognitive impairment, dementia with Lewy bodies, and Alzheimer's disease. They demonstrated the promise of deep learning with PET imaging in the early detection of dementia by achieving high accuracy in dementia diagnosis. The study highlights the importance of developing accurate and efficient tools for early diagnosis of dementia. (Etminani K, mild cognitive impairment using brain 18F-FDG PET., 2022)

The study by H.W. Kim et al. suggests a deep learning-based method for classifying

Alzheimer's disease using PET scans. The authors employed a multi-slice CNN model for feature extraction and classification on a collection of PET images. Their remarkable prediction accuracy for Alzheimer's disease highlights the promise of PET imaging and deep learning as non-invasive early diagnosis tools. According to the study, this method might be helpful in creating an Alzheimer's disease computer-aided diagnosis system. (Woong Kim Han, 2020)

In their study, Vasco S¬a Diogo et al. provide a multi-diagnostic, broadly applicable model for early Alzheimer's disease diagnosis based on machine learning. The Alzheimer's Disease Neuroimaging Initiative (ADNI) provided the data, and the authors classified it using machine learning techniques like Random Forest and Support Vector Machine. They were highly accurate in their early diagnosis predictions of Alzheimer's disease, indicating that the suggested method may be a useful aid in the early detection of the condition. The study emphasises the potential of multi-diagnostic approaches and machine learning for early Alzheimer's disease identification. (Diogo VS, 2022)

In their study, Vinu Thomas and P.C. Muhammad Raees suggest a deep learning-based method for automatically identifying Alzheimer's disease using magnetic resonance imaging (MRI). The scientists employed a Support Vector Machine (SVM) classifier for disease identification after applying Convolutional Neural Networks (CNNs) to extract pertinent characteristics from MRI images. The suggested technique demonstrated encouraging outcomes in identifying Alzheimer's disease, indicating that deep learning-based methods may be helpful for an early and precise diagnosis. The research emphasises the potential of MRI and machine learning as non-invasive methods of diagnosing Alzheimer's disease. Thomas Raees, 2021)

Numerous scholars have taken notice of the study by V. P. Nithya*, N. Mohanasundaram, and R. Santhosh, which suggests the prediction of moderate cognitive impairment or Alzheimer's disease (AD). As the condition is becoming more common, earlier diagnosis is necessary. Unfortunately, building an effective computer diagnostic system is highly requested because of the high-dimensionality of neurological data and the scarcity of available samples. Disease prediction requires the

application of learning methodologies, particularly deep learning methodologies.The superior performance of deep learning (DL) techniques has been effectively proven in a number of domains, including medical imaging. Using magnetic resonance imaging (MRI) data, a novel 3D-Convolutional Neural Network (3D-CNN) architecture is presented to predict AD. While the current methods perform binary classification and lack prediction accuracy, the proposed model predicts the occurrence of AD. The Neuro-Imaging Initiative (ADNI) data related to Alzheimer's disease is used to validate the suggested prediction model. The results show that the expected model outperforms the general methods using the brain-image dataset and achieves improved prediction accuracy. Because the feature learning is adaptable, the predicted model lessens the amount of human labour required throughout the prediction process and facilitates intelligent diagnosis. Experiments using Keras are conducted, and the model's superiority is evaluated against a range of sophisticated multi-level classification techniques. In comparison to other systems such as Long Short Term Memory-Recurrent Neural Networks (LSTM-RNN), Stacked Autoencoder with Deep Neural Networks (SAE-DNN), Deep Convolutional Neural Networks (D-CNN), Two Dimensional Convolutional Neural Networks (2D-CNN), Inception-V4, ResNet, and Two Dimensional Convolutional Neural Networks (3D-CNN), the proposed model provides better prediction accuracy, precision, recall, and F-measure. (V. P. Nithya, N. Mohanasundaram, R. Santhosh, 2023)

According to a report by Zi-Chao Zhang, Xingzhong Zhao, Guiying Dong, and Xing-Ming Zhao, fluorodeoxyglucose (FDG) or florbetapir (AV45) combined with positron emission tomography (PET) has been shown to be a useful diagnostic tool for Alzheimer's disease. However, PET's use has been restricted due to its high cost and radioactive nature. Here, we present a deep learning model—the 3-dimensional multi-task multi-layer perceptron mixer—that uses multi-layer perceptron mixer architecture to simultaneously predict the standardised uptake value ratios (SUVRs) for FDG-PET and AV45-PET from low-cost, commonly-used structural magnetic resonance imaging data. Based on embedding features derived from SUVR prediction, the model can also be used to diagnose Alzheimer's disease. The results of the experiment show that the suggested method for FDG/AV45-PET SUVRs has a high

prediction accuracy. We were able to obtain Pearson's correlation coefficients of 0.66 and 0.61 between the estimated and actual SUVRs, respectively. The estimated SUVRs also exhibit high sensitivity and unique longitudinal patterns for various disease states. The proposed method, which considers PET embedding features, achieves better results than other competing methods on five independent datasets for both the diagnosis of Alzheimer's disease and the differentiation of mild cognitive impairments that are stable and progressive. On the ADNI dataset, the proposed method achieves area under receiver operating characteristic curves of 0.968 and 0.776, respectively, and shows better generalisation to other external datasets. Moreover, the top-weighted patches extracted from the trained model involve important brain regions related to Alzheimer's disease, suggesting good biological interpretability of our proposed method.(Zi-Chao Zhang, Xingzhong Zhao, Guiying Dong, Xing-Ming Zhao, 2023)

Product Survey

The studies that were evaluated point to a number of products or possible uses for MRI and PET scan data that might be created to help with the early detection of diabetes and Alzheimer's disease.

Aberatne, Iroshan et al. This work offers a potentially useful machine learning method for utilising MRI and PET neuroimaging data to detect Alzheimer's disease early. The suggested approach has the potential to be a non-invasive tool for early diagnosis and demonstrates great accuracy in predicting the start of Alzheimer's disease. Researchers and physicians treating patients with Alzheimer's disease may find this method useful if it is further validated.

In order to diagnose Alzheimer's disease, this research suggests methods using machine learning and visual processing. An evolutionary algorithm is used in the suggested framework to enhance the accuracy of classification and optimise the feature selection procedure. If put to the test, this paradigm might offer a precise and effective way to identify Alzheimer's disease early on.

In study by S. Aslantas et al., a machine learning approach for retinal imaging-based

early Alzheimer's disease detection is proposed. According to the study's encouraging findings, retinal imaging may be a non-invasive method for identifying Alzheimer's disease early on. If further research confirms this method, it might offer a quick and easy way to identify Alzheimer's disease in its early stages.

In the study by Narotam Singh et al. An analysis. This study presents a thorough review of current research on the automated use of deep neural networks with MRI data for Alzheimer's disease identification. This study emphasises the need for additional validation of machine-based technologies and their promise for early Alzheimer's disease identification. Physicians and researchers studying Alzheimer's disease may find the information this review offers to be helpful.

In a study by Etminani Kobra et al. In this work, a 3D deep learning model that uses brain 18FFDG PET imaging to predict the diagnosis of Lewy body dementia, Alzheimer's disease, and cognitive impairment is presented. The suggested approach has good classification accuracy, indicating its potential for use as a neurodegenerative disease diagnostic tool. If more trustworthy, this method might offer a precise and non-invasive means of diagnosing this illness.

Kim Han Woong et al. This study uses positron emission tomography (PET) imaging to suggest a multislice imaging approach for the classification of Alzheimer's disease. The suggested approach, which makes use of convolutional neural networks, achieves good classification accuracy, indicating its potential for application as an Alzheimer's disease diagnostic tool. If successful, this procedure could offer a precise and non-invasive way to diagnose Alzheimer's disease.

San Diego Vasco et al. This study describes a multi-diagnostic, machine learning-based method for utilising clinical and neuroimaging data to detect Alzheimer's disease early. The suggested approach demonstrates a high degree of accuracy in anticipating the start of Alzheimer's disease and indicates its potential for use as a diagnostic tool for the early identification of the condition. If verified, this method may prove to be an invaluable resource for researchers and doctors dealing with Alzheimer's disease.

A deep learning-based method for automated Alzheimer's disease identification using

MRI scans is presented in "Automated detection of Alzheimer's Disease using Deep Learning in MRI" by P.C. Muhammad Raees and Vinu Thomas. The suggested technique uses a deep neural network for preprocessing, segmentation, feature extraction, and classification. According to the study, deep learning has a high degree of accuracy when it comes to early Alzheimer's disease identification.

The study by V. P. Nithya, N. Mohanasundaram, and R. Santhosh tackles the urgent need for precise early detection and prediction of mild cognitive impairment, also known as Alzheimer's disease (AD). The disease is becoming more common, and this has drawn a lot of attention from researchers. The high-dimensionality of brain data and the dearth of available samples are acknowledged as issues in the research that call for the creation of effective computer-based diagnostic methods. Using deep learning techniques, in particular the newly suggested 3D-Convolutional Neural Network (3D-CNN) architecture, is a major advancement for the prediction of AD from magnetic resonance imaging (MRI) material.

The research by Zi-Chao Zhang, Xingzhong Zhao, Guiying Dong, and Xing-Ming Zhao presents a novel method to overcome the limitations of PET in Alzheimer's disease diagnosis. PET with fluorodeoxyglucose (FDG) or florbetapir (AV45) has shown promise, but its radioactive nature and high cost prevent it from being used widely. The study uses a deep learning model that predicts Standardised Uptake Value Ratios (SUVRs) for FDG-PET and AV45-PET simultaneously from commonly used structural Magnetic Resonance Imaging (MRI) data in order to get around these limitations. The result is a 3-dimensional multi-task multi-layer perceptron mixer.

All things considered, these findings demonstrate the promise of deep learning and machine learning for automated early diagnosis and detection of Alzheimer's disease using MRI, PET, and retinal imaging, among other imaging modalities. Better patient outcomes may result from the use of these strategies by doctors in early intervention and treatment.

2.2 Limitation of State of the Art techniques

1. Lack of standardized diagnostic criteria:

• The field lacks consensus on specific imaging biomarkers and features indicative of Alzheimer's disease.

• Standardized diagnostic criteria are essential for accurate and reliable detection.

2. Variation in imaging biomarkers and features:

• Different studies use diverse imaging biomarkers (e.g., brain structure, connectivity, metabolism).

• Lack of standardized protocols for image acquisition, preprocessing, and feature extraction.

• Variations in methods can lead to inconsistent results and hinder comparison across studies.

3. Interpretation and analysis inconsistencies:

• Different algorithms and techniques used to extract features from MRI and PET scans.

• Choice of methods significantly impacts model performance.

• Lack of standardized feature extraction methods and guidelines.

4. Limitations of training and evaluation datasets:

• Relatively small datasets used in many studies.

• Small datasets may not fully capture disease heterogeneity and complexity.

• Imbalanced class distributions, with fewer Alzheimer's disease cases than healthy controls.

• Imbalance can bias results and reduce generalizability.

2.2.1 Potential solutions and areas for improvement 1. Standardized protocols and diagnostic criteria:

• Establishing consensus on imaging biomarkers and features.

• Standardized protocols for image acquisition, preprocessing, and feature extraction.

• Clear guidelines to ensure consistency across studies.

2. Larger, diverse datasets:

• Utilizing large-scale datasets that encompass disease heterogeneity.

• Ensuring balanced class distributions to improve model performance and generalizability.

• Collaborative efforts and data sharing initiatives to facilitate access to diverse datasets.

3. Collaboration and research coordination:

• Encouraging collaboration between research groups and institutions.

• Sharing resources, expertise, and methodologies.

• Promoting consistency and reproducibility of findings.

2.3 Discussion and future direction

2.4 Concluding Remarks

In this discussion, we explored the limitations of state-of-the-art techniques for Alzheimer's disease detection using MRI and PET scan data. It is evident that several challenges hinder the accuracy and reliability of these techniques. The lack of standardized diagnostic criteria, variation in imaging biomarkers and features, inconsistencies in interpretation and analysis methods, and limitations of training and evaluation datasets all contribute to the limitations faced by current approaches.

To overcome these limitations, it is crucial to focus on potential solutions and areas for improvement. Standardizing protocols and diagnostic criteria will ensure consistency and comparability across studies. This involves establishing a consensus

on imaging biomarkers and features, as well as implementing standardized protocols for image acquisition, preprocessing, and feature extraction. Additionally, the availability of larger and more diverse datasets is essential to capture the heterogeneity and complexity of Alzheimer's disease accurately. Collaborative efforts, data sharing initiatives, and research coordination among institutions and research groups will facilitate the pooling of resources, expertise, and methodologies, leading to more robust and reproducible findings.

Addressing these limitations will have significant implications for early Alzheimer's disease detection and its potential application in clinical practice. By improving the accuracy and reliability of techniques using MRI and PET scan data, clinicians can make more informed decisions and provide appropriate interventions at an early stage of the disease. Furthermore, standardized approaches and larger datasets will enhance the generalizability of the models, allowing for wider application and better understanding of Alzheimer's disease.

Enhancing the accuracy of Alzheimer's disease detection requires a concerted effort towards standardizing image analysis techniques and defining consistent imaging biomarkers. Establishing standardized protocols for image acquisition, preprocessing methods, and feature extraction algorithms is crucial. By ensuring consistency in these processes, researchers can mitigate variations arising from different methodologies and equipment, leading to more reliable and comparable results across studies.

Combining information from multiple imaging modalities, such as MRI and PET scans, along with other biomarkers like genomics or cerebrospinal fluid markers, could offer a more comprehensive understanding of AD progression. Integration of these multimodal data through advanced machine learning techniques, such as multimodal fusion models or graph-based approaches, might reveal intricate patterns and relationships not discernible from individual modalities alone, potentially improving diagnostic accuracy and disease characterization.

Ethical concerns regarding patient privacy and data sharing hinder access to larger, diverse datasets necessary for robust machine learning model development. Encouraging collaborative efforts, open data sharing initiatives while maintaining patient

privacy, and creating standardized repositories for AD-related imaging and clinical data can foster the creation of more extensive and representative datasets. Furthermore, partnerships with healthcare institutions, regulatory bodies, and funding agencies are pivotal in establishing guidelines and frameworks that facilitate responsible data sharing while safeguarding patient confidentiality.

The ultimate goal is to translate research findings into clinical applications. Bridging the gap between research and clinical practice requires validation and standardization of developed models in clinical settings. Collaborations between researchers, clinicians, and regulatory bodies can facilitate the validation and regulatory approval of these AI-driven diagnostic tools, ensuring their safe and effective integration into routine clinical workflows.

In conclusion, the limitations discussed in this chat highlight the need for continued research and development in the field of Alzheimer's disease detection. By addressing these limitations through standardized protocols, larger datasets, and collaborative efforts, we can strive for more accurate and reliable techniques that will ultimately contribute to improved patient care, early intervention, and a better understanding of this devastating disease.

Chapter 3

Problem Definition and Scope

The project focuses on enhancing Alzheimer's Disease (AD) detection methodologies through machine learning and medical imaging. The primary goal is to overcome existing limitations and improve diagnostic accuracy for early AD detection. The project scope involves leveraging three datasets – Oasis-2 longitudinal database, MRI images, and 3D imaging data – for comprehensive analysis. Ensemble learning, CNNs on MRI images, and ResNet3D for 3D imaging aim to extract features, patterns, and biomarkers associated with AD. The project emphasizes algorithmic innovation, comparative evaluation, and ethical considerations, contributing to AD detection advancement and patient care. The scope does not include clinical implementation but lays the groundwork for future diagnostic tools in AD. In summary, the project aims to significantly contribute to improving AD detection and understanding its pathology.

The project addresses the challenge of early and accurate detection of Alzheimer's disease (AD), a neurodegenerative disorder with significant global impact. Existing diagnostic methods suffer from subjectivity, limited sensitivity in early stages, and reliance on time-intensive procedures. To overcome these limitations, the project leverages machine learning and medical imaging across three datasets: Oasis-2, MRI images, and 3D imaging data.

The Oasis-2 dataset is used with an ensemble learning approach to differentiate between demented and non-demented individuals, reducing subjectivity and inter-rater

variability. The MRI image dataset employs convolutional neural network (CNN) models for predicting dementia severity, enabling early measurement of AD progression. Integration of 3D imaging and ResNet architecture enhances volumetric insights into brain structures, addressing the limitations of current diagnostic methods.

By combining diverse datasets and advanced methodologies, the project aims to revolutionize AD detection, improving accuracy and enabling earlier identification of the disease. The goal is to develop a comprehensive diagnostic framework, leveraging machine learning and imaging for effective interventions and personalized patient care. Ultimately, the project contributes to the advancement of AD diagnosis, striving for more precise tools and improved patient outcomes.

3.1 Goals and Objectives

The primary objective of this project is to evaluate and compare three distinct methodologies for Alzheimer's Disease (AD) detection, utilizing diverse databases—Oasis-2 longitudinal, MRI images, and 3D imaging. Leveraging machine learning and medical imaging, the specific goals are:

1. **Ensemble Learning Models on Oasis-2:** Train and evaluate ensemble learning models (decision trees, random forests, gradient boosting) on the Oasis-2 database to differentiate between demented and non-demented individuals. Evaluate accuracy, precision, recall, and F1 score for optimal model selection.

2. **CNN Model on MRI Images:** Train a Convolutional Neural Network (CNN) on the MRI image database to predict dementia severity. Classify individuals into dementia classes and assess the CNN model's accuracy in capturing relevant features and patterns.

3. **Integration of 3D Imaging Data:** Incorporate 3D imaging data for volumetric insights into brain structures. Analyze AD-related anatomical alterations, capturing intricate spatial details and providing a three-dimensional perspective of affected brain regions.

3.2 Scope and Major Constraints

This section delineates the comprehensive scope and essential constraints of the project. The ambitious scope involves a meticulous exploration and comparison of three pivotal methodologies: the Oasis-2 longitudinal database, MRI image sets, and the integration of 3D imaging, all aimed at detecting and analyzing Alzheimer's Disease (AD). Leveraging a convergence of machine learning algorithms and advanced medical imaging techniques, the project aspires to formulate and refine methods for diagnosing AD. However, this ambitious endeavor is accompanied by inherent constraints and considerations that shape the project's execution and outcomes.

Scope:

- **Oasis-2 Longitudinal Database:** Evaluate ensemble learning on annealed and unannealed samples to differentiate smoking and non-smoking individuals, unraveling AD-related patterns.
- **MRI Image Database:** Utilize Convolutional Neural Network (CNN) models for predicting dementia severity based on MRI scans, categorizing individuals into distinct classes.
- **Integration of 3D Imaging:** Pioneering the use of 3D imaging for volumetric exploration of brain structures associated with AD, unraveling intricate spatial details and three-dimensional representations.
- **Comparative Analysis:** Assess and compare outcomes between ensemble learning on Oasis-2, CNN models on MRI images, and 3D imaging, understanding strengths and limitations of each methodology.

Key Limitations:

- **Database Availability and Quality:** Results depend on the availability, completeness, and reliability of Oasis-2, MRI image, and 3D imaging datasets.

- **Resource Intensiveness:** Computational demands for training ensemble models, CNN architectures, and processing 3D data require robust computing resources.
- **Ethical and Privacy Considerations:** Adherence to ethical and privacy standards is crucial when handling sensitive medical data, especially concerning 3D imaging, MRI images, and patient records.
- **Generalizability and Clinical Implementation:** Considerations regarding the project's applicability to diverse populations and clinical settings, along with the practicality of deploying advanced detection methods.

3.3 Hardware and Software Requirements

The successful execution of the AD detection project on Google Colab with GPU acceleration necessitates specific hardware and software configurations for optimal performance:

Hardware Requirements:

- **Virtual Machine (VM) on Google Colab:** Leveraging Google Colab's GPU-accelerated virtual machine is essential for efficient handling of large datasets and computational tasks.
- **Processor:** The VM's processor capability is managed by Google Colab, ensuring sufficient computational power for the project's requirements.
- **Memory (RAM):** Colab provides access to a high-RAM environment, eliminating concerns about memory constraints. The dynamic allocation meets the demands of extensive datasets and complex analyses.
- **Storage:** Google Colab integrates with Google Drive, offering substantial storage capacity for datasets, code, and intermediate results without local storage limitations.

- **Graphics Processing Unit (GPU):** Colab provides access to a GPU, enhancing the performance of deep learning algorithms and accelerating computations. A GPU with a minimum of 12 GB VRAM is typically available.

Software Requirements:

- **Operating System:** As a cloud-based service, Google Colab eliminates OS concerns, ensuring compatibility regardless of the local system.
- **Python:** Colab supports Python 3.x, providing a versatile environment with access to a myriad of libraries and frameworks for machine learning and data analysis.
- **Integrated Development Environment (IDE):** Jupyter Notebooks, the default environment in Google Colab, facilitates seamless development and experimentation.
- **Data Processing and Analysis Libraries:** NumPy, Pandas, and Scikit-learn are readily available in Colab, serving essential functions for data manipulation, statistical analysis, and machine learning.
- **Deep Learning Frameworks:** TensorFlow and PyTorch are pre-installed in Colab, empowering the implementation of deep learning algorithms without additional setup.
- **Image Processing Libraries:** Colab supports popular image processing libraries like OpenCV, simplifying MRI and PET scan data preprocessing, feature extraction, and visualization.
- **Statistical Analysis Software:** Optional depending on project requirements, R or SPSS can be installed in Colab via package managers.
- **Visualization Tools:** Matplotlib, Seaborn, and Plotly are readily accessible in Colab, enabling data visualization and insightful plot generation.

3.4 Expected Outcomes

- **Accurate Diagnostic Classification:** Develop a robust model for precise brain tumor classification as malignant or benign, achieving high accuracy, sensitivity, and specificity.
- **Validation Metrics:** Establish comprehensive metrics (accuracy, sensitivity, specificity, precision, recall, F1-score, AUC-ROC) to rigorously evaluate the model's performance and reliability.
- **Generalizability and Transferability:** Develop a model capable of generalizing across diverse brain tumor images and adaptable to various medical settings, ensuring real-world applicability.
- **Contribution to Medical Research:** Disseminate research findings through publications and presentations, contributing to advancements in medical image analysis and brain tumor classification.
- **Potential for Future Expansion:** Position the outcomes as a foundation for future research, potentially expanding into related medical imaging domains or refining existing approaches for enhanced accuracy.

Chapter 4

System Requirement Specification

4.1 Overall Description

In the dynamic landscape of medical diagnostics, the development of advanced technologies holds the promise of revolutionizing healthcare practices. This System Requirement Specification (SRS) delineates the foundational framework for a cutting-edge Alzheimer classification system. As a critical component in the realm of medical imaging, this system aims to provide accurate and timely classifications of Alzheimers, supporting healthcare professionals in treatment planning and decision-making. The following sections encapsulate the comprehensive requirements, functionalities, and performance expectations of the Alzheimer classification system. By articulating specific user needs, external interfaces, and functional intricacies, this SRS serves as a guiding document for the development of a sophisticated diagnostic tool poised to enhance patient care and contribute to the broader landscape of medical research.

4.1.1 Hardware Requirements

- High-performance system with multicore processor (2.5 GHz or higher).
- Minimum 8 GB RAM; recommended 16 GB or more.
- At least 500 GB HDD or SSD.

- Dedicated GPU with a minimum of 4 GB VRAM (optional but recommended).

4.1.2 Software Requirements

- Operating System: Windows, macOS, or Linux.
- Python 3.x for machine learning and data analysis.
- IDE: PyCharm, Anaconda, or Jupyter Notebook.
- Libraries: NumPy, Pandas, Scikit-learn for data manipulation.
- Deep Learning Frameworks: TensorFlow or PyTorch.
- Image Processing Libraries: OpenCV or SimpleITK.
- Visualization Tools: Matplotlib, Seaborn, or Plotly.

4.2 Development Requirements

4.2.1 Data Access

Access to relevant datasets is crucial for training and evaluating the Alzheimer's Disease classification models. The following databases are required:

- Oasis-1 Longitudinal Database
- MRI Image Database
- Oasis-1 3D Imaging Data

Ensure that permissions and ethical considerations are addressed when accessing and using medical datasets.

4.3 Tech Stack

The technology stack for developing the Alzheimer's Disease classification system involves a combination of programming languages, libraries, and frameworks. The

recommended tech stack includes:

- **Programming Language:** Python
- **Deep Learning Frameworks:** TensorFlow or PyTorch
- **Machine Learning Libraries:** Scikit-learn, NumPy, Pandas
- **Data Visualization:** Matplotlib, Seaborn, Plotly
- **Development Environment:** Jupyter Notebook, PyCharm, Anaconda

This tech stack provides a comprehensive and powerful set of tools for developing, training, and evaluating machine learning models for Alzheimer's Disease classification. Adjustments can be made based on specific preferences and project requirements.

4.4 Project Planning

4.4.1 Gantt Chart

The project will be executed in a systematic manner, adhering to a well-defined timeline. The following milestones and corresponding timeframes provide an overview of the project's planned progression:

- **Project Initiation (Month 1):** Define project scope, objectives, and deliverables. Establish communication channels and collaboration tools.
- **Literature Review (Months 2-3):** Conduct an extensive review of relevant literature on Alzheimer classification, machine learning in medical imaging, and existing methodologies.
- **Data Collection and Preprocessing (Months 4-5):** Gather datasets, including the Oasis-2 longitudinal database, MRI image sets, and 3D imaging data. Preprocess the data to ensure consistency and relevance.

- **Model Development (Months 6-8):** Implement machine learning algorithms and deep learning architectures for Alzheimer classification. Experiment with ensemble learning on the Oasis-2 dataset, CNN models on MRI images, and ResNet3D on 3D imaging data.

- **Model Evaluation (Months 9-10):** Evaluate the developed models using appropriate metrics such as accuracy, precision, recall, and F1-score. Refine models based on evaluation results.

- **Integration and Comparative Analysis (Months 11-12):** Integrate the developed models into a cohesive framework. Conduct a comparative analysis to understand the strengths and limitations of each methodology.

- **Documentation and Reporting (Months 13-14):** Prepare comprehensive documentation, including the System Requirement Specification (SRS) and technical reports. Compile research findings for dissemination.

- **Validation and Testing (Months 15-16):** Validate the models across diverse datasets and scenarios. Perform rigorous testing to ensure the generalizability and robustness of the developed Alzheimer classification system.

- **Finalization and Presentation (Months 17-18):** Finalize the project deliverables, including code repositories, technical documentation, and presentation materials. Present the project outcomes and findings.

Chapter 5

Methodology

The methodology encompasses three key components for Alzheimer's disease prediction: OASIS 1 CSV dataset using Ensemble Learning, MRI images dataset using CNN, and 3D images using ResNet3D.

For the OASIS 1 CSV dataset, the process begins with collecting and preprocessing the longitudinal dataset, addressing missing values and encoding features. Feature engineering is employed to enhance predictive power, and an ensemble of models, including Logistic Regression, Support Vector Machines, and others, is trained. The ensemble Voting Classifier is then formed based on accuracy, interpretability, and relevance, enabling accurate Alzheimer's disease prediction.

In the case of MRI images, data is collected, preprocessed, and standardized. A suitable CNN architecture, such as VGG or ResNet, is chosen for image classification. The model is trained to extract hierarchical representations and meaningful features from MRI images. Hyperparameter tuning and optimization enhance performance, and the model is evaluated using validation and test sets, with interpretations visualized to understand influential image regions.

For 3D images, the methodology involves collecting and preprocessing the 3D MRI dataset, choosing the ResNet3D architecture for processing, and training the model to extract hierarchical features. Hyperparameter tuning and optimization are applied, and the model's performance is evaluated using validation and test sets. Interpretability techniques are then employed to visualize model activations and un-

derstand influential image regions.

These streamlined processes provide a comprehensive framework for Alzheimer's disease prediction, leveraging diverse datasets and advanced techniques in ensemble learning, CNN, and ResNet3D.

5.1 System Architecture

5.1.1 Figure 5.1: System Architecture for OASIS CSV Dataset

The system architecture depicted in Figure 5.1 illustrates the workflow designed for processing the OASIS CSV dataset. The data processing pipeline involves several key stages, including data loading, preprocessing, feature extraction, and model training. Initially, the raw CSV data is loaded into the system, where preprocessing steps such as data cleaning and normalization are applied to ensure the quality and consistency of the dataset. Subsequently, relevant features are extracted from the preprocessed data to be used as input for the machine learning models. Finally, the system incorporates various machine learning algorithms for training and evaluation, aiming to classify and predict Alzheimer's disease based on the OASIS CSV dataset.



Figure 5.1: System Architecture for OASIS CSV Dataset

5.1.2 Figure 5.2: System Architecture for MRI

The system architecture presented in Figure 5.2 outlines the processing pipeline tailored for MRI data. MRI images play a crucial role in understanding structural changes in the brain associated with Alzheimer's disease. The depicted architecture involves stages such as image acquisition, preprocessing, and the utilization of Convolutional Neural Networks (CNNs) for classification tasks. The acquired MRI images undergo preprocessing steps, including normalization and enhancement, to optimize their quality for subsequent analysis. The CNN model, integrated into the system, is trained to learn intricate patterns within the images, enabling accurate classification and diagnosis of Alzheimer's disease based on structural information captured by MRI scans.

5.1.3 Figure 5.3: System Architecture for 3D Dataset

Figure 5.3 illustrates the system architecture tailored for processing 3D datasets, particularly focusing on 3D ResNet-18 model architecture. The three-dimensional nature of the data, such as MRI scans, requires specialized neural network architectures capable of capturing spatial dependencies. The ResNet-18 architecture is employed for its effectiveness in learning hierarchical features from volumetric data. The system involves loading and preprocessing 3D datasets, followed by the application of the ResNet-18 model for feature extraction and classification. The intricacies of the neural network's architecture contribute to its ability to discern complex patterns within the 3D dataset, enhancing the accuracy of Alzheimer's disease diagnosis.

These system architectures showcase the adaptability of the proposed methodologies to diverse datasets, each tailored to the unique characteristics of the input data type. The comprehensive processing pipelines aim to leverage the strengths of machine learning and deep learning techniques for effective Alzheimer's disease detection and classification.

5.2 Mathematical Modeling

5.2.1 Logistic Regression

Logistic Regression models the probability of an event occurring as a function of one or more predictor variables. The logistic function is defined as:

$$\text{Logit Function: } \text{logit}(p) = \ln\left(\frac{p}{1-p}\right)$$

$$\text{Probability Prediction: } p(y=1|x) = \frac{1}{1+e^{-(\beta_0+\beta_1 x_1+\beta_2 x_2+\ldots+\beta_n x_n)}}$$

5.2.2 Support Vector Machines (SVM)

Support Vector Machines find the hyperplane that best separates classes in the feature space. The hyperplane equation is given by:

$$\text{Hyperplane Equation: } \mathbf{w}\cdot\mathbf{x} - b = 0$$

$$\text{Decision Function: } f(\mathbf{x}) = \mathbf{w}\cdot\mathbf{x} - b$$

5.2.3 AdaBoost

AdaBoost combines multiple weak classifiers to create a strong ensemble model. The ensemble function is represented as:

$$F(\mathbf{x}) = \sum_{t=1}^{T} \alpha_t f_t(\mathbf{x})$$

5.2.4 Gaussian Naive Bayes

Gaussian Naive Bayes is based on Bayes' theorem with the assumption of feature independence. The probability prediction is given by:

$$P(y|\mathbf{x}) = \frac{1}{Z} P(y) \prod_{i=1}^{n} P(x_i|y)$$

5.2.5 CatBoost

CatBoost is a gradient boosting algorithm that incorporates category-based features. The ensemble function is represented as:

$$F(\mathbf{x}) = \sum_{i=1}^{T} b_t(\mathbf{x})$$

5.2.6 Multilayer Perceptron (MLP)

Multilayer Perceptron is a type of artificial neural network with multiple layers. The forward pass equations for each layer are given by:

$$z_j^l = \sum_k w_{jk}^l a_k^{l-1} + b_j^l$$

$$a_j^l = \sigma(z_j^l)$$

5.2.7 XGBoost

XGBoost is an optimized gradient boosting algorithm. The ensemble function is represented as:

$$F(\mathbf{x}) = \sum_{i=1}^{T} f_t(\mathbf{x})$$

5.2.8 Decision Tree

A Decision Tree partitions the feature space into regions and assigns a label to each region.

5.2.9 InceptionV3 (CNN Architecture)

InceptionV3 is a Convolutional Neural Network (CNN) architecture known for its inception modules. The inception module equations for convolution and pooling are given by:

$$\text{Inception Convolution: } y = \sigma(W_c * x + b_c)$$

$$\text{Inception Pooling: } y = \text{maxpool}(x)$$

5.2.10 ResNet (ResNet3D Architecture)

ResNet is a Residual Neural Network architecture for processing 3D image data. The residual block is represented as:

$$\text{Residual Block: } y = F(x, \{W_i\}) + x$$

Layer (type)	Output Shape	Param #
inception_v3 (Functional)	(None, 1, 1, 2048)	21802784
dropout_5 (Dropout)	(None, 1, 1, 2048)	0
global_average_pooling2d (GlobalAveragePooling2D)	(None, 2048)	0
flatten_1 (Flatten)	(None, 2048)	0
batch_normalization_101 (B atchNormalization)	(None, 2048)	8192
dense_4 (Dense)	(None, 512)	1049088
batch_normalization_102 (B atchNormalization)	(None, 512)	2048
dropout_6 (Dropout)	(None, 512)	0
dense_5 (Dense)	(None, 256)	131328
batch_normalization_103 (B atchNormalization)	(None, 256)	1024
dropout_7 (Dropout)	(None, 256)	0
dense_6 (Dense)	(None, 128)	32896
batch_normalization_104 (B atchNormalization)	(None, 128)	512
dropout_8 (Dropout)	(None, 128)	0
dense_7 (Dense)	(None, 64)	8256
dropout_9 (Dropout)	(None, 64)	0
batch_normalization_105 (B atchNormalization)	(None, 64)	256
dense_8 (Dense)	(None, 4)	260

Total params: 23036644 (87.88 MB)
Trainable params: 1227844 (4.68 MB)
Non-trainable params: 21808800 (83.19 MB)

Figure 5.2: System Architecture for MRI

Layer Name	3D ResNet-18	Output Size
conv1	$5 \times 5 \times 5$, 64, stride(2,2,2)	$32 \times 38 \times 32 \times 64$
Max Pool	$1 \times 3 \times 3$ max pool, stride(1,2,2)	$32 \times 19 \times 16 \times 64$
Res-block 1	$\begin{bmatrix} 1 \text{ x } 3 \text{ x } 3, 64, \text{stride}(1,1,1) \\ 1 \text{ x } 3 \text{ x } 3, 64, \text{stride}(1,1,1) \end{bmatrix} \times 2$	$32 \times 19 \times 16 \times 64$
Res-block 2	$\begin{bmatrix} 1 \text{ x } 3 \text{ x } 3, 128, \text{stride}(1,2,2) \\ 1 \text{ x } 3 \text{ x } 3, 128, \text{stride}(1,1,1) \end{bmatrix} \times 2$	$32 \times 10 \times 8 \times 128$
Res-block 3	$\begin{bmatrix} 3 \text{ x } 3 \text{ x } 3, 256, \text{stride}(1,2,2) \\ 3 \text{ x } 3 \text{ x } 3, 256, \text{stride}(1,1,1) \end{bmatrix} \times 2$	$32 \times 5 \times 4 \times 256$
Res-block 4	$\begin{bmatrix} 3 \text{ x } 3 \text{ x } 3, 512, \text{stride}(1,2,2) \\ 3 \text{ x } 3 \text{ x } 3, 512, \text{stride}(1,1,1) \end{bmatrix} \times 2$	$32 \times 3 \times 2 \times 512$
Average Pool	$32 \times 3 \times 2$ average pool	$1 \times 1 \times 1 \times 512$
Fully connected	512×2 fully connected layer	2

Figure 5.3: System Architecture for 3D dataset

Chapter 6

Implementation

The following section outlines the implementation details of various machine learning algorithms for the task of predicting dementia.

6.1 Algorithms for CSV Data

6.1.1 Logistic Regression (LR)

Regularized logistic regression is employed with a specified parameter C. The key evaluation metrics include accuracy, precision, F1-score, and recall.

6.1.2 Support Vector Machine (SVM)

A linear SVM classifier is utilized with a specified kernel and regularization parameter C. Similar to LR, performance metrics are computed.

6.1.3 Decision Tree (DT)

Decision Tree classifier is implemented with a specified maximum depth and cost-complexity pruning parameter. Evaluation metrics include accuracy, precision, F1-score, and recall.

6.1.4 Random Forest (RF)

Random Forest classifier is employed with a specified number of trees, maximum depth, minimum samples split, and cost-complexity pruning parameter. Evaluation metrics are calculated for model assessment.

6.1.5 Adaboost (AdaBoost)

AdaBoost classifier is used with a specified base estimator (Decision Tree) and the number of weak learners. Similar evaluation metrics are computed.

6.1.6 K-Nearest Neighbors (KNN)

KNN classifier is utilized with a specified number of neighbors. Performance metrics are calculated.

6.1.7 Gaussian Naive Bayes (GNB)

Naive Bayes classifier is employed with Gaussian distribution assumption. Evaluation metrics are calculated.

6.1.8 XGBoost (XGB)

XGBoost classifier is used without explicit parameter tuning. Similar performance metrics are computed.

6.1.9 LightGBM (LGB)

LightGBM classifier is implemented without specific parameter adjustments. Evaluation metrics are calculated.

6.1.10 CatBoost (Cat)

CatBoost classifier is utilized with specified learning rate and number of estimators. Performance metrics are calculated.

6.1.11 Passive Aggressive Classifier (PAC)

Passive Aggressive classifier is used with a specified regularization parameter and maximum number of iterations. Similar performance metrics are computed.

6.1.12 Voting Classifier (Vote)

A simple majority voting mechanism is applied using predictions from SVM, AdaBoost, and GNB. Performance metrics for the ensemble model are computed.

The script concludes with a bar chart comparing the accuracies of various models and an ROC curve illustrating the performance of each algorithm in terms of false positive rate vs. true positive rate. The final voting classifier provides an ensemble prediction based on the majority vote from selected models.

6.2 Alzheimer Disease Prediction Using MRI Images

6.2.1 Exploratory Data Analysis

The implementation begins with exploratory data analysis. MRI images are loaded and visualized to gain insights into the dataset. The dataset is observed to be imbalanced, with varying numbers of images in each category.

6.2.2 Data Preprocessing

To address the imbalance, the SMOTE (Synthetic Minority Over-sampling Technique) is applied. The dataset is split into training and testing sets, and SMOTE is used to oversample the minority classes.

6.2.3 Convolutional Neural Network (CNN) Model

A CNN model is defined and trained using the preprocessed data. The model includes convolutional and dense blocks.

6.2.4 Transfer Learning with InceptionV3 Model

The implementation explores transfer learning using the InceptionV3 model. The pre-trained InceptionV3 is fine-tuned for the specific task.

6.3 3D MRI Images

In this section, we provide details on the implementation of our 3D Convolutional Neural Network (CNN) model using PyTorch. The code is organized into three parts, corresponding to the model architecture, data loading and preprocessing, and the training loop.

6.3.1 Data Loading and Preprocessing

We developed a custom dataset class, `CustomDataset`, responsible for loading and preprocessing MRI images. It utilizes the `nibabel` library to handle NIfTI images and incorporates various methods for data retrieval, transformation, and normalization.

6.3.2 ResNet18_3D

The ResNet-18 3D model is composed of multiple layers of the `BasicBlock3D`. It includes the initial convolutional layer, batch normalization, ReLU activation, max-pooling, and four residual layers. The model concludes with an adaptive average pooling layer and a fully connected layer for classification.

6.3.3 Training Loop

The training loop involves iterating over the training dataset, computing forward and backward passes, optimizing model parameters, and evaluating the model on the validation set.

6.3.4 Results and Analysis

We trained the models using a specified criterion, optimizer, and number of epochs. The training and validation losses, accuracies, and a confusion matrix were calculated and visualized for performance analysis.

6.4 Experiment/Implementation Parameters

In the pursuit of developing accurate and robust models for predicting dementia in the OASIS dataset, various machine learning algorithms were employed. Each algorithm comes with a set of hyperparameters that play a crucial role in determining the model's performance. This table (6.1) provides an overview of the key hyperparameters utilized in different algorithms, showcasing the specific configurations chosen for this study.

The table 6.2 provides an overview of the hyperparameters used in the Alzheimer Disease prediction models based on MRI images. Two main approaches were employed: Convolutional Neural Network (CNN) and Transfer Learning using the InceptionV3 model.

The 3D ResNet-18 architecture is a convolutional neural network designed for processing three-dimensional data, often used in tasks such as video analysis or medical imaging. This table (6.3) outlines the key hyperparameters employed in configuring the 3D ResNet-18 model. These hyperparameters play a crucial role in shaping the architecture and behavior of the network during training and inference. The chosen values reflect specific configurations tailored to the requirements of the task at hand, ensuring optimal performance and feature extraction capabilities.

6.5 Data Description

6.5.1 OASIS CSV Dataset

The OASIS CSV dataset comprises structured data stored in a Comma-Separated Values (CSV) format. This dataset is focused on Alzheimer's disease research and may include features such as demographic information, clinical assessments, and cognitive scores. The CSV format allows for easy manipulation and analysis of tabular data. Key variables may include participant IDs, age, gender, education level, and various cognitive test scores. The 6.1 shows the correlation of all the features.



Figure 6.1: Correlation Matrix of OASIS CSV Dataset

6.5.2 MRI Images Dataset

The MRI images dataset consists of medical imaging data in the form of two-dimensional (2D) images. These images are typically acquired through Magnetic Resonance Imaging (MRI) scans and are used for Alzheimer's disease prediction. Each image represents a slice of the brain, and the dataset includes images from individuals with different levels of dementia. Common characteristics include im-

age resolution, image size, and grayscale intensity values. The 6.2 are some sample images from the dataset.



Figure 6.2: Sample MRI Images from MRI Dataset

6.5.3 3D ResNet-18 Dataset

The 3D ResNet-18 dataset involves three-dimensional (3D) data processed using a ResNet-18 architecture. This dataset is often used for more advanced analyses, capturing spatial information in addition to 2D details. The 3D ResNet-18 model is applied to extract features and patterns from volumetric data, providing a more comprehensive understanding of brain structures. The dataset may include 3D volumes, labels indicating dementia severity, and other relevant metadata. The 6.3 is a sample image slice (mid slice) from one of the nifti files.

Each dataset type serves a specific purpose in Alzheimer's disease prediction, contributing unique information to the overall analysis. Combining these diverse datasets allows for a holistic approach to understanding and predicting the progression of



Figure 6.3: Sample 3D Slices (Mid Slice) From one of the nifti files.

Alzheimer's disease.

6.6 Output

The classification results are presented for various machine learning models applied to predict Alzheimer's disease based on different datasets and methodologies.

6.6.1 OASIS CSV Data

The models were trained and evaluated using the OASIS CSV dataset. Performance metrics such as accuracy, precision, recall, and F1-score were computed for each model. Additionally, a voting ensemble method was employed to combine predictions from multiple models, providing a comprehensive assessment of the overall classification performance.

6.6.2 MRI Images Data

For the MRI images dataset, both custom convolutional neural network (CNN) models and a transfer learning approach using the InceptionV3 model were employed. The training and validation processes, along with corresponding accuracy trends, are visualized. The ensemble of CNN models was also utilized to generate predictions and assess the overall accuracy.



Figure 6.4: Accuracy Bar graph



Figure 6.5: Model training accuracy and loss curves

6.6.3 3D ResNet-18 Results

The 3D ResNet-18 architecture was applied to the volumetric dataset. A summary of hyperparameters used for training is provided. The training history, including metrics like accuracy, AUC, and loss, is illustrated for transfer learning model.

The results offer insights into the effectiveness of different models and methodologies in predicting Alzheimer's disease across diverse datasets.

6.7 Standard Industry Practice Adopted

The industry practices for developing Alzheimer's Disease classification systems involve key steps:



Figure 6.6: Traning loss Curve ResNet183D



Figure 6.7: Validation Loss Curve ResNet183D

1. **Data Handling:**
    - Collect a diverse and representative dataset.
    - Preprocess data for consistency and quality.
2. **Model Selection:**
    - Choose suitable models like CNNs or ensemble methods.
    - Explore advanced architectures (e.g., ResNet3D, InceptionV3).
3. **Evaluation:**
    - Use standard metrics (accuracy, precision, recall, F1-score).
    - Implement cross-validation for robustness.
4. **Interpretability:**



Figure 6.8: Training and Validation Accuracy ResNet183D

- Apply techniques like activation mapping for model interpretation.

5. **Ensemble Learning:**
   - Explore ensemble methods (e.g., Voting Classifiers) for improved performance.
6. **Hyperparameter Tuning:**
   - Systematically optimize hyperparameters for better model performance.
7. **Tools and Libraries:**
   - Use industry-standard tools (TensorFlow, PyTorch, scikit-learn).
8. **Documentation:**
   - Document the process and results, including the SRS.

Adopting these practices ensures a systematic and effective approach to developing reliable Alzheimer's Disease classification systems.

Algorithm	**Hyperparameter**	**Value**
Logistic Regression (LR)	C (Regularization)	0.1
Support Vector Machine (SVM)	Kernel	Linear
	C (Regularization)	10
	Probability	True
Decision Tree (DT)	Max Depth	3
	CCP Alpha	0.1
Random Forest (RF)	Number of Estimators	60
	Max Depth	6
	Min Samples Split	4
	CCP Alpha	0.01
AdaBoost	Base Estimator	DT
	Number of Estimators	15
K-Nearest Neighbors (KNN)	Number of Neighbors	3
CatBoost	Learning Rate	0.5
	Number of Estimators	100
Passive Aggressive Classifier (PAC)	C	0.1
	Max Iterations	200
	No Change Iterations	3

Table 6.1: Hyperparameters for Different Algorithms for OASIS CSV Dataset

Hyperparameter	Value
Image Size (CNN)	128
Dropout Rate (CNN)	0.2
Batch Size (CNN)	6500
Learning Rate (CNN)	Adam optimizer
Number of Epochs (CNN)	10
Dropout Rate (InceptionV3)	0.5
Dense Layer 1 Size (InceptionV3)	512
Dense Layer 2 Size (InceptionV3)	256

Table 6.2: Alzheimer Disease Prediction Hyperparameters

Hyperparameter	Value
Input Channels	1
Initial Convolution Kernel Size	7
Initial Convolution Filters	64
Batch Normalization (Initial)	Yes
Residual Blocks per Layer	2
Residual Block Channels	64, 128, 256, 512
Adaptive Average Pooling Size	(1, 1, 1)
Fully Connected Layer Size	1

Table 6.3: Hyperparameters for 3D ResNet-18

Chapter 7

Result Analysis/Performance Evaluation

The outcome of the Alzheimer's disease classification system is scrutinized through an in-depth result analysis and performance evaluation. This section delves into the performance metrics, including accuracy, precision, recall, and F1-score, offering a comprehensive understanding of the models' effectiveness. A comparative analysis highlights the strengths and weaknesses of individual algorithms and their ensemble. Interpretability and visualization techniques are employed to elucidate influential features within medical images. The discussion extends to the generalization and robustness of the models, tested across diverse datasets. Ethical considerations regarding patient data privacy and responsible model deployment are also integral aspects of this analysis.

7.1 Result Analysis of Objective 1: Ensemble Learning on Oasis-1

The application of ensemble learning models, including decision trees, random forests, and gradient boosting, on the Oasis-2 longitudinal database yielded compelling results, effectively distinguishing between demented and non-demented individuals. The models exhibited high accuracy, precision, recall, and F1 score, as showcased

in Table 7.1. Notably, the Voting Classifier, with a remarkable accuracy of 95.6%, emerged as the top-performing algorithm, emphasizing its efficacy in capturing intricate patterns within longitudinal data. The comprehensive set of performance metrics serves as concrete evidence of the successful achievement of Objective 1.

Algorithm	**Accuracy**	**Precision**	**F1-score**	**Recall-score**
Logistic Regression	0.867	1.0	0.824	0.7
SVM	0.889	1.0	0.848	0.737
Decision Tree	0.933	0.929	0.897	0.867
Random Forest	0.889	0.929	0.839	0.765
MLP	0.311	1.0	0.475	0.311
K-Nearest Neighbors	0.644	0.571	0.5	0.444
Gaussian Naive Bayes	0.911	1.0	0.875	0.778
XGBoost	0.844	1.0	0.8	0.667
LightGBM	0.889	1.0	0.848	0.737
CatBoost	0.867	1.0	0.824	0.7
Passive Aggressive Classifier	0.311	1.0	0.475	0.311
Voting Classifier	0.956	1.0	0.933	0.875

Table 7.1: Performance Metrics of Various Algorithms

7.2 Result Analysis of Objective 2: CNN Model on MRI Images

The Convolutional Neural Network (CNN) trained on MRI images exhibited remarkable performance in predicting dementia severity. The model showcased its proficiency in accurately classifying individuals into distinct dementia categories,

emphasizing its capability to discern subtle image features indicative of Alzheimer's Disease (AD) progression. The achieved high accuracy underscores the significance of leveraging deep learning techniques for image-based AD diagnosis, paving the way for precise and automated assessments.

Class	**Precision**	**Recall**	**F1-Score**	**Support**
NonDemented	0.94	0.95	0.94	639
VeryMildDemented	1.00	1.00	1.00	635
MildDemented	0.85	0.79	0.82	662
ModerateDemented	0.78	0.83	0.81	624
Micro Avg	0.89	0.89	0.89	2560
Macro Avg	0.89	0.89	0.89	2560
Weighted Avg	0.89	0.89	0.89	2560
Samples Avg	0.89	0.89	0.89	2560

Table 7.2: Detailed Classification Metrics for CNN Model

The detailed evaluation metrics, including precision, recall, and F1-score, further validate the model's effectiveness in capturing nuanced patterns associated with different stages of dementia. The Balanced Accuracy Score of 89.14% and Matthew's Correlation Coefficient of 85.46% provide quantitative measures affirming the CNN model's robust performance in contributing to advanced methodologies for AD detection using MRI images.

7.3 Result Analysis of Objective 3: Integration of 3D Imaging Data

The integration of 3D imaging data provided comprehensive insights into the volumetric aspects of brain structures affected by Alzheimer's Disease (AD). As evi-

denced in Table 7.3, the training and validation metrics over 10 epochs showcase the model's learning progress. The model achieved high accuracy on the validation set, underscoring the effectiveness of the 3D imaging integration in capturing meaningful patterns associated with AD. This concrete evidence supports the achievement of Objective 3, marking a significant step toward refining AD detection methodologies by leveraging the volumetric information offered by 3D imaging.

Epoch	**Train Loss**	**Train Acc (%)**	**Val Loss**	**Val Acc (%)**
1	72.5757	62.25	5.8586	65.00
2	56.9263	70.25	28.4468	62.50
3	45.2477	79.50	41.5236	52.50
4	34.5702	84.50	11.2818	70.00
5	34.6141	85.75	45.4350	55.00
6	26.8959	90.50	9.2059	75.00
7	29.4228	86.75	1.5550	92.50
8	23.5477	90.50	1.0233	95.00
9	16.9351	94.75	3.3569	87.50
10	10.6032	97.25	1.2634	95.00

Table 7.3: Training and Validation Metrics over 10 Epochs

Chapter 8

Conclusion

8.1 Conclusion

The comprehensive result analysis and performance evaluation provide valuable insights into the Alzheimer's disease classification system. The amalgamation of ensemble learning on the Oasis-2 dataset, a CNN model on MRI images, and the integration of 3D imaging data contributes to a multifaceted approach for AD detection.

8.2 Key Findings

The ensemble learning models, encompassing decision trees, random forests, and gradient boosting, demonstrated exceptional accuracy in distinguishing between demented and non-demented individuals. The Voting Classifier emerged as the top-performing algorithm, attaining an impressive accuracy of 95.6%. This success establishes the efficacy of ensemble learning in capturing intricate patterns within longitudinal data.

The CNN model trained on MRI images exhibited remarkable performance in predicting dementia severity. Achieving high accuracy and detailed classification metrics, the model showcased its proficiency in discerning subtle image features indicative of AD progression. The Balanced Accuracy Score of 89.14% and Matthew's Correlation Coefficient of 85.46% further affirm the model's robust performance.

The integration of 3D imaging data provided comprehensive insights into the volumetric aspects of brain structures affected by AD. The model's learning progress, as evidenced in the training and validation metrics over 10 epochs, underscores the effectiveness of 3D imaging integration in capturing meaningful patterns associated with AD.

In conclusion, the multifaceted approach to AD detection, encompassing ensemble learning, CNN models, and 3D imaging integration, has shown promising results. The findings contribute to the ongoing efforts to develop accurate, reliable, and ethical diagnostic tools for Alzheimer's disease. The combination of different methodologies provides a comprehensive understanding of AD-related patterns, paving the way for advancements in the field.

8.3 Future Scope

The outcomes of this study open avenues for future research and improvements in Alzheimer's disease detection methodologies. Several aspects merit attention for future investigations:

- **Interpretability and Explainability:** Enhance the interpretability of models to provide clearer insights into the decision-making process. Developing methods for explaining the models' predictions can foster trust and understanding, especially in clinical settings.
- **Integration of Multi-Modal Data:** Explore the integration of multiple imaging modalities, such as combining MRI images with other neuroimaging techniques or biomarker data. This holistic approach could enhance the overall accuracy and reliability of AD detection models.
- **Real-World Clinical Deployment:** Transitioning models from research environments to real-world clinical settings requires rigorous validation and adherence to ethical guidelines. Future work should focus on the practical deployment of models, considering factors such as scalability, usability, and integration with existing healthcare systems.

- **Longitudinal Studies and Progressive Monitoring:** Conduct longitudinal studies to track the progression of Alzheimer's disease over time. Implementing models for progressive monitoring and predicting disease trajectories could provide valuable insights for personalized treatment plans.
- **Collaborative Research and Data Sharing:** Foster collaboration and data sharing among research institutions and healthcare providers. Large, diverse datasets can contribute to the development of more robust and generalizable models.
- **Ethical Guidelines and Patient Consent:** Establish and adhere to comprehensive ethical guidelines for handling patient data. Ensuring explicit and informed consent from patients for data usage is crucial, emphasizing the importance of privacy and ethical considerations in medical AI research.

The future scope outlined above signifies the ongoing commitment to advancing Alzheimer's disease research and improving diagnostic capabilities. As technology evolves and more data becomes available, continued exploration and innovation will be essential for addressing the complex challenges associated with AD detection and patient care.

Appendices

Appendix A

Dataset and Code Files

A.1 Datasets

The datasets used in this study are available in the following Google Drive folder: https://drive.google.com/drive/folders/1O0uVrxT35cAAdmUcb5dxJCZKTdoPiWcY?usp=sharing

A.2 Code Files

The code files, including Jupyter Notebook (IPYNB) files, associated with this study can be found in the following Google Drive folder: https://drive.google.com/drive/folders/1O0uVrxT35cAAdmUcb5dxJCZKTdoPiWcY?usp=sharing

Appendix B

About OASIS

The Open Access Series of Imaging Studies (OASIS) is a commendable initiative that provides researchers with open access to a rich collection of neuroimaging datasets. OASIS aims to foster scientific advancements in understanding brain structures and functions, particularly in the context of conditions like Alzheimer's disease.

B.1 Accessing OASIS

To explore and benefit from the OASIS datasets, visit the official OASIS website at `https://oasis-brains.org/`. The website serves as a central hub where researchers can access information about the datasets, their structure, and relevant details for utilization.

B.2 OASIS Data Use Agreement

Before diving into the datasets, researchers are required to adhere to the OASIS Data Use Agreement. This agreement outlines terms and conditions related to privacy, acknowledgment, citation, and compliance. Refer to *Appendix C* for a detailed explanation of the Data Use Agreement.

B.3 Conclusion

OASIS stands as a valuable resource in the field of neuroimaging, contributing to the collaborative efforts of researchers worldwide. This appendix serves as a guide for researchers interested in leveraging the OASIS datasets for their studies.

Appendix C

Publication: Emerging System & Intelligent Computing 2024



Appendix D

Plagiarism Report of Text

Alzheimer Disease

ORIGINALITY REPORT

14%	11%	9%	3%
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS

PRIMARY SOURCES

1	shropsys.com Internet Source	1%
2	www.unboundmedicine.com Internet Source	1%
3	www.techscience.com Internet Source	1%
4	www.mdpi.com Internet Source	1%
5	doctorpenguin.com Internet Source	1%
6	www.researchgate.net Internet Source	<1%
7	Submitted to Coventry University Student Paper	<1%
8	Submitted to Liverpool John Moores University Student Paper	<1%
9	Zi-Chao Zhang, Xingzhong Zhao, Guiying Dong, Xing-Ming Zhao. "Improving	<1%

References

Battineni G, C. N. T. E. D. V. R. M. A. F., Hossain MA. (2021). Improved alzheimer's disease detection by mri using multimodal machine learning algorithms. *Diagnostics (Basel)*.

Data were provided oasis: Cross-sectional: Principal investigators: D. marcus, r, buckner, j, csernansky j. morris; p50 ag05681, p01 ag03991, p01 ag026276, r01 ag021910, p20 mh071616, u24 rr021382 by oasis. (n.d.). *https://doi.org/10.1162/jocn.2007.19.9.1498*.

Diogo VS, P. D., Ferreira HA. (2022). Alzheimer's disease neuroimaging initiative. early diagnosis of alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach. *Alzheimers Res Ther.*.

Etminani K, D. A. C. J. M.-S. B. B. S. C. V. B. M. S. R. R. M. A.-C. M. C. A. B. M. R. A. B. R. V. R. K. M. T. M., Soliman A. (2022). A 3d deep learning model to predict the diagnosis of dementia with lewy bodies, alzheimer's disease, and mild cognitive impairment using brain 18f-fdg pet. *Eur J Nucl Med Mol Imaging.*.

Haller, S., Jäger, H. R., Vernooij, M. W., & Barkhof, F. (2023). Neuroimaging in dementia: more than typical alzheimer disease. *Radiology*, *308*(3), e230173.

Kang, W., Lin, L., Sun, S., & et al. (2023). Three-round learning strategy based on 3d deep convolutional gans for alzheimer's disease staging. *Sci Rep*, *13*, 5750. doi: 10.1038/s41598-023-33055-9

Kim Han Woong, K. L.-S. Y. M. Y. S. K., Lee Ha Eun Oh. (2020). Multi-slice representational learning of convolutional neural network for alzheimer's disease classification using positron emission tomography. *BioMedical Engineering OnLine*.

Kim S, O. K. B. M. Y. D. L. J. K. Y. Y. B. Y. M. L. D. J. Y., Lee P. (2021). Alzheimer's disease neuroimaging initiative; kbase research group. deep learning-based amyloid

pet positivity classification model in the alzheimer's disease continuum by using 2-[18f]fdg pet. *EJNMMI Res.*.

Koundal, K. M. P. A. R. N. M. Z. A. S. N. P. R. M. S. S. K. S. F., Deepika. (2022). Machine learning and image processing enabled evolutionary framework for brain mri analysis for alzheimer's disease detection. *Hindawi*.

Kwak, M. G., Su, Y., Chen, K., & et al. (2023). Self-supervised contrastive learning to predict the progression of alzheimer's disease with 3d amyloid-pet. *Bioengineering*, *10*, 1141. doi: 10.3390/bioengineering10101141

Lin W, G. Q. G. D. D. X. Y. Y. G. G. X. M. D. M. Q. X., Tong T. (2018a). Alzheimer's disease neuroimaging initiative. convolutional neural networks-based mri image analysis for the alzheimer's disease prediction from mild cognitive impairment. *Front Neurosci.*.

Lin W, G. Q. G. D. D. X. Y. Y. G. G. X. M. D. M. Q. X., Tong T. (2018b). Alzheimer's disease neuroimaging initiative. convolutional neural networks-based mri image analysis for the alzheimer's disease prediction from mild cognitive impairment. *Front Neurosci.*.

Maysam Orouskhani, S. R. F. S. Z. M. S. Y. O., Chengcheng Zhu (Ed.). (2022). Alzheimer's disease detection from structural mri using conditional deep triplet network.

Memon, Z., Turab, M., Narejo, S., & Korejo, M. T. (2023). An ensemble of cnn architectures for early detection of alzheimer's disease using brain mri. *Mehran University Research Journal of Engineering and Technology*, *42*(4), 140–147.

Nithya, V. P., Mohanasundaram, N., & Santhosh, R. (2023). Earlier detection of alzheimer's disease using 3d-convolutional neural networks. *Computer Systems Science and Engineering*, *46*(2), 2601–2618.

Raees, P. C. M., & Thomas, V. (2021, may). Automated detection of alzheimer's disease using deep learning in mri. *Journal of Physics: Conference Series*, *1921*(1), 012024. Retrieved from `https://dx.doi.org/10.1088/1742-6596/1921/1/012024` doi: 10.1088/1742-6596/1921/1/012024

Rao, K. N., Gandhi, B. R., Rao, M. V., Javvadi, S., & Vellela, S. S. (2023). Prediction and classification of alzheimer's disease using machine learning techniques in 3d mr images. In *2023 international conference on sustainable computing and smart systems (icscss)* (pp. 85–90). doi: 10.1109/ICSCSS57650.2023.10169550

Singh, N., D, P., Soni, N., & Kapoor, A. (2022). *Automated detection of alzheimer disease*

using mri images and deep neural networks- a review.

Thamizhvani, T., Hemalatha, R., Rachel Cynthia, V., & Swetha, S. (2023). Analysis of raw 3d images of stages of alzheimer's disease using deep learning. In *2023 international conference on bio signals, images, and instrumentation (icbsii)* (pp. 1–5). doi: 10 .1109/ICBSII58188.2023.10181077

Thangavel, P., Natarajan, Y., & Preethaa, K. S. (2023). Ead-dnn: Early alzheimer's disease prediction using deep neural networks. *Biomedical Signal Processing and Control*, *86*, 105215. doi: 10.1016/j.bspc.2023.105215

Thangavel, P., Natarajan, Y., & Sri Preethaa, K. R. (2023). Ead-dnn: Early alzheimer's disease prediction using deep neural networks. *Biomedical Signal Processing and Control*, *86*, 105215. doi: 10.1016/j.bspc.2023.105215

Thota, N. R., & Vasumathi, D. (2023). Wasserstein gan-gradient penalty with deep transfer learning for 3d mri alzheimer disease classification.

Venugopalan, J., Tong, L., Hassanzadeh, H. R., & Wang, M. (2021, 02). Multimodal deep learning models for early detection of alzheimer's disease stage. *Scientific Reports*, *11*, 3254. doi: 10.1038/s41598-020-74399-w

Xin, J., Wang, A., Guo, R., Liu, W., & Tang, X. (2023). Cnn and swin-transformer based efficient model for alzheimer's disease diagnosis with smri. *Biomedical Signal Processing and Control*, *86*, 105189.

Yiming Ding, M. G. K. H. T. R. H. N. W. J. D. L. T. P. C. M. S. A. C. M. A. S. C. B. R. R. F. S.-Y. H. K. A. Z. L. N. Y. S. R. A. H. M. H. P. D. H., Jae Ho Sohn, & Franc, B. L. (1992). A deep learning model to predict a diagnosis of alzheimer disease by using 18f-fdg pet of the brain.

Yuvaraj, N., Preethi, T., Sumathi, A. C., & Sri Preethaa, K. R. (2023). Alzheimer disease classification based on multimodel deep convolutional neural network using mri images. *AIP Conf. Proc.*, *2764*(1), 060008. doi: 10.1063/5.0144082

Zhang, Y., Teng, Q., He, X., Niu, T., Zhang, L., Liu, Y., & Ren, C. (2023). Attention-based 3d cnn with multi-layer features for alzheimer's disease diagnosis using brain images. *ArXiv*.

Zhang, Z. C., Zhao, X., Dong, G., & Zhao, X. M. (2023, Aug). Improving alzheimer's disease diagnosis with multi-modal pet embedding features by a 3d multi-task mlp-mixer neural network. *IEEE Journal of Biomedical and Health Informatics*, *27*(8), 4040–4051. doi: 10.1109/JBHI.2023.3280823

Zhao Z, L. K. C. C. G. M. D. S. W. N. B. W. W. X., Chuah JH (Ed.). (2023). Conventional machine learning and deep learning in alzheimer's disease diagnosis using neuroimaging: A review.

Zheng, B., Gao, A., Huang, X., Li, Y., Liang, D., & Long, X. (2023). A modified 3d efficientnet for the classification of alzheimer's disease using structural magnetic resonance images. *IET Image Process*, *17*, 77–87. doi: 10.1049/ipr2.12618